SOURCE: Amarillo Biosciences, Inc.

April 03, 2007 08:50 ET

Amarillo Biosciences to Be Featured in Exclusive MN1.com Interview

AMARILLO, TX -- (MARKET WIRE) -- April 3, 2007 -- Joseph Cummins, CEO of Amarillo Biosciences, Inc. (OTCBB: AMAR), will join Market News First for an interview scheduled for Tuesday, April 3, 2007 at 10:15 a.m. CDT at www.mn1.com.

Amarillo Biosciences is focused on the research and development activities to develop biologics for the treatment of human and animal diseases.

Among topics of interest, Cummins will talk about the Company's ongoing clinical studies of the Turkish Behcet's Disease and the Phase II clinical trial of oral warts in HIV positive patients.

Other Amarillo Biosciences news includes its annual shareholders' meeting to take place in June and its intentions to establish commercial partnerships and licenses in 2007.

To learn more about the Company, its goals toward progression and success, log on to www.mn1.com Tuesday, April 3.

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 13% of Amarillo Biosciences shares and has provided over $17.8 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behçet's disease, and opportunistic infections in patients who are HIV positive. In its 22-year history, ABI has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for oral interferon therapies. Additional information is available on the ABI web site at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2006.

About MN1.com

Market News First is an online market news provider that brings investors current news on the market. Market News First is the only online, live IPTV web site that brings real market news to investors and features live interaction with companies from the Bulletin Board to NYSE.

Through daily, live interviews, we bring you up to date on all the established companies and inform the investors of the newest opportunities within the market. Market News First offers one-on-one interviews with the presidents and CFOs of companies to deliver answers to the questions that investors may ask and provides them insight into the companies' present condition and future plans.

Contact Information

  • Investor Relations:
    Philippe Niemetz
    PAN Consultants, Ltd.
    e-mail: p.niemetz@panconsultants.com
    Tel: 800-477-7570; 212-344-6464
    Fax: 212-618-1276

    Joseph M. Cummins, DVM, PhD
    Amarillo Biosciences, Inc.
    e-mail: jcummins@amarbio.com
    Tel: 806-376-1741 x 13
    Fax: 806-376-9301